These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36841655)

  • 1. [Does aspirin have a place in primary cardiovascular prevention by the polypill ? Simulation study on a realistic virtual population].
    Fall M; Grenet G; Le HH; Kassaï B; Lega JC; Boussageon R; Mainbourg S; Marchant I; Gafsi J; Dieye AM; Gueyffier F
    Therapie; 2023; 78(6):667-678. PubMed ID: 36841655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
    Sanmuganathan PS; Ghahramani P; Jackson PR; Wallis EJ; Ramsay LE
    Heart; 2001 Mar; 85(3):265-71. PubMed ID: 11179262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70).
    Sugawara M; Goto Y; Yamazaki T; Teramoto T; Oikawa S; Shimada K; Uchiyama S; Ando K; Ishizuka N; Murata M; Yokoyama K; Uemura Y; Ikeda Y;
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):299-311. PubMed ID: 30565155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polypill with or without Aspirin in Persons without Cardiovascular Disease.
    Yusuf S; Joseph P; Dans A; Gao P; Teo K; Xavier D; López-Jaramillo P; Yusoff K; Santoso A; Gamra H; Talukder S; Christou C; Girish P; Yeates K; Xavier F; Dagenais G; Rocha C; McCready T; Tyrwhitt J; Bosch J; Pais P;
    N Engl J Med; 2021 Jan; 384(3):216-228. PubMed ID: 33186492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis.
    Joseph P; Roshandel G; Gao P; Pais P; Lonn E; Xavier D; Avezum A; Zhu J; Liu L; Sliwa K; Gamra H; Bangdiwala SI; Teo K; Diaz R; Dans A; Lopez-Jaramillo P; Prabhakaran D; Castellano JM; Fuster V; Rodgers A; Huffman MD; Bosch J; Dagenais GR; Malekzadeh R; Yusuf S;
    Lancet; 2021 Sep; 398(10306):1133-1146. PubMed ID: 34469765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.
    Barrios V; Kaskens L; Castellano JM; Cosin-Sales J; Ruiz JE; Zsolt I; Fuster V; Gracia A
    Rev Esp Cardiol (Engl Ed); 2017 Jan; 70(1):42-49. PubMed ID: 27474481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.
    Berger JS; Roncaglioni MC; Avanzini F; Pangrazzi I; Tognoni G; Brown DL
    JAMA; 2006 Jan; 295(3):306-13. PubMed ID: 16418466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polypill Strategy in Secondary Cardiovascular Prevention.
    Castellano JM; Pocock SJ; Bhatt DL; Quesada AJ; Owen R; Fernandez-Ortiz A; Sanchez PL; Marin Ortuño F; Vazquez Rodriguez JM; Domingo-Fernández A; Lozano I; Roncaglioni MC; Baviera M; Foresta A; Ojeda-Fernandez L; Colivicchi F; Di Fusco SA; Doehner W; Meyer A; Schiele F; Ecarnot F; Linhart A; Lubanda JC; Barczi G; Merkely B; Ponikowski P; Kasprzak M; Fernandez Alvira JM; Andres V; Bueno H; Collier T; Van de Werf F; Perel P; Rodriguez-Manero M; Alonso Garcia A; Proietti M; Schoos MM; Simon T; Fernandez Ferro J; Lopez N; Beghi E; Bejot Y; Vivas D; Cordero A; Ibañez B; Fuster V;
    N Engl J Med; 2022 Sep; 387(11):967-977. PubMed ID: 36018037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of Coronary Artery Calcium Scanning in Association With the Net Benefit of Aspirin in Primary Prevention of Atherosclerotic Cardiovascular Disease.
    Ajufo E; Ayers CR; Vigen R; Joshi PH; Rohatgi A; de Lemos JA; Khera A
    JAMA Cardiol; 2021 Feb; 6(2):179-187. PubMed ID: 33112372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force.
    Wolff T; Miller T; Ko S
    Ann Intern Med; 2009 Mar; 150(6):405-10. PubMed ID: 19293073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    ; Bowman L; Mafham M; Wallendszus K; Stevens W; Buck G; Barton J; Murphy K; Aung T; Haynes R; Cox J; Murawska A; Young A; Lay M; Chen F; Sammons E; Waters E; Adler A; Bodansky J; Farmer A; McPherson R; Neil A; Simpson D; Peto R; Baigent C; Collins R; Parish S; Armitage J
    N Engl J Med; 2018 Oct; 379(16):1529-1539. PubMed ID: 30146931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
    Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
    N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
    Carey KM; Comee MR; Donovan JL; Kanaan AO
    Ann Pharmacother; 2012 May; 46(5):688-95. PubMed ID: 22570437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of aspirin treatment strategies for primary prevention of cardiovascular diseases: A decision-analytic Markov modelling study].
    Zhang ML; Liu QP; Gong C; Wang JM; Zhou TJ; Liu XF; Shen P; Lin HB; Tang X; Gao P
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Jun; 55(3):480-487. PubMed ID: 37291924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis.
    Zheng SL; Roddick AJ
    JAMA; 2019 Jan; 321(3):277-287. PubMed ID: 30667501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
    Gaziano TA; Pandya A; Sy S; Jardim TV; Ogden JM; Rodgers A; Weinstein MC
    Am Heart J; 2019 Aug; 214():77-87. PubMed ID: 31174054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease.
    Gallagher H; Dumbleton J; Maishman T; Whitehead A; Moore MV; Fuat A; Fitzmaurice D; Henderson RA; Lord J; Griffith KE; Stevens P; Taal MW; Stevenson D; Fraser SD; Lown M; Hawkey CJ; Roderick PJ
    Trials; 2022 Apr; 23(1):331. PubMed ID: 35449015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.
    Bhatt DL; Steg PG; Mehta SR; Leiter LA; Simon T; Fox K; Held C; Andersson M; Himmelmann A; Ridderstråle W; Chen J; Song Y; Diaz R; Goto S; James SK; Ray KK; Parkhomenko AN; Kosiborod MN; McGuire DK; Harrington RA;
    Lancet; 2019 Sep; 394(10204):1169-1180. PubMed ID: 31484629
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.